Medicinal products for the treatment of blood coagulation disorders

Abstract

A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.

1 . A thrombin-free factor-XIa concentrate or a thrombin-free coagulation factor concentrate containing factor XIa for the manufacture of a pharmaceutical preparation which does not form thrombin during storage, and for the manufacture of a parenterally applicable drug product which does not form thrombin during or after freeze-drying, storage and reconstitution. 
     
     
         2 . The pharmaceutical preparation according to  claim 1 , which contains serpins and/or high molecular weight kininogen or its split products. 
     
     
         3 . The pharmaceutical preparation according to  claim 1 , which is nanofiltered to improve viral safety, either before or after formulation. 
     
     
         4 . The pharmaceutical preparation according to  claim 1 , which is rendered virally safe by treatment with solvent/detergent and subsequent removal of solvent and detergent. 
     
     
         5 . The pharmaceutical preparation according to  claim 1 , which is filled under sterile and pyrogen-free conditions and is freeze-dried and virally inactivated by heating the filled, freeze-dried pharmaceutical preparations at no less than 90° C. and no more than 140° C. for 30 to 180 minutes. 
     
     
         6 . Thrombin-free factor-XIa concentrate or thrombin-free coagulation factor concentrate containing factor XIa according to  claim 1 , which is obtained by fractionation of plasma or serum or by genetic engineering. 
     
     
         7 . Thrombin-free factor-XIa concentrate or thrombin-free coagulation factor concentrate containing factor XIa according to  claim 1 , which are virally safe and pyrogen-free. 
     
     
         8 . A diagnostic kit comprising:
 one or more components configured for the determination of the amount of factor-XIa concentrate which is necessary to normalize prolonged blood coagulation in a reference factor-VIII inhibitor plasma and in blood samples of patients with coagulation disorders.   
     
     
         9 . A method of manufacturing a medicinal drug product for treatment of coagulation disorders, the method comprising:
 providing the thrombin-free factor-XIa concentrate or a thrombin-free coagulation factor concentrate containing factor XIa of  claim 1 ; and   preparing a medicinal drug product from the thrombin-free factor-XIa concentrate or a thrombin-free coagulation factor concentrate containing factor XIa as an active ingredient.   
     
     
         10 . The pharmaceutical preparation of  claim 3 , wherein the nanofiltering uses a nanofilter with a pore diameter of ≦20 nm. 
     
     
         11 . The pharmaceutical preparation of  claim 3 , wherein the nanofiltering uses a nanofilter is a 1000 kDalton ultrafilter. 
     
     
         12 . A pharmaceutical preparation comprising:
 a thrombin-free factor-XIa concentrate or a thrombin-free coagulation factor concentrate containing factor XIa which does not form thrombin during storage.   
     
     
         13 . The pharmaceutical preparation of  claim 12 , wherein the pharmaceutical preparation is configured as a parenterally applicable drug product which does not form thrombin during or after freeze-drying, storage and reconstitution. 
     
     
         14 . The pharmaceutical preparation according to  claim 12 , which contains serpins and/or high molecular weight kininogen or its split products. 
     
     
         15 . The pharmaceutical preparation according to  claim 12 , which is nanofiltered to improve viral safety, either before or after formulation. 
     
     
         16 . The pharmaceutical preparation of  claim 15 , wherein the nanofiltering uses a nanofilter with a pore diameter of ≦20 nm. 
     
     
         17 . The pharmaceutical preparation of  claim 15 , wherein the nanofiltering uses a nanofilter is a 1000 kDalton ultrafilter. 
     
     
         18 . The pharmaceutical preparation according to  claim 1 , which is rendered virally safe by treatment with solvent/detergent and subsequent removal of solvent and detergent. 
     
     
         19 . The pharmaceutical preparation according to  claim 1 , which is filled under sterile and pyrogen-free conditions and is freeze-dried and virally inactivated by heating the filled, freeze-dried pharmaceutical preparations at no less than 90° C. and no more than 140° C. for 30 to 180 minutes. 
     
     
         20 . The pharmaceutical preparation according to  claim 1 , which is virally safe and pyrogen-free.